EBOS Group's healthcare segment demonstrated robust performance in the first half of 2024, with revenue reaching $6.3 billion and EBITDA hitting $275.5 million, marking increases of 7.5% and 8.0%, respectively.
In Australia, healthcare revenue rose to $5 billion, with underlying EBITDA increasing to $228.6 million, driven by market leadership and margin management.
New Zealand and Southeast Asia saw healthcare revenue grow to $1.3 billion, while underlying EBITDA slightly decreased to $46.8 million due to COVID-19-related factors.
Community pharmacy revenue surged by $181.0 million, with notable growth in retail brands like TerryWhite Chemmart and increased wholesale market share.
Excluding revenue from COVID-19-related anti-viral medications, community pharmacy delivered normalised revenue of 8.3%.
Institutional healthcare revenue also saw a significant uptick, driven by Symbion Hospitals and Medical Technology businesses.
Revenue increased by $205.8 million up 11.7% and gross operating revenue increased by $11.7 million up 6%.
These results underscore EBOS' strong position and growth potential in the healthcare sector.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Feb 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Feb 24
